Immunotherapy Experience in Melanoma Integrating IO into Clinical Practice Sanjiv S. Agarwala, MD
|
|
- Erica Willis
- 5 years ago
- Views:
Transcription
1 Immunotherapy Experience in Melanoma Integrating IO into Clinical Practice Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA
2 Overview Current Therapy for Melanoma BRAF-WT patient BRAF+ patient Immunotherapy side effects management and practical considerations
3 Transforming the Landscape Immunotherapy Target host Hit a Target Targeted Therapy Target tumor
4 Immuno-oncology Timeline Clinical Developments William Coley Mixed Toxins 1882 Allogeneic BM transplantation Steinman Dendritic Cells Laboratory Discoveries BCG Bladder Cancer Hepatitis B Vaccine Zinkernagel & Doherty MHCI Tcell recognition First trial with IL-2 First trial Adoptive T cells in cancer First trial with IFNa Melanoma Interferons cloned Boon, Rosenberg Characterisation 1 st HumanTumour Antigens TNFa Isolated limb perfusion melanoma & sarcoma Sakaguchi Rediscovery of Tregs Burnett Cancer Immunosurveillance Non-myeloablative chemorx & adoptive T cell melanoma Discovery of TLRs Allison CTLA4 blockade enhances cancer immunity Chen & Pardoll PD-1 Ligands identified Imiquimod VIN 2011 Regulatory approvals FDA: Brentuximab acd30 HD&AnLC Lymphoma FDA Ipi Melanoma 2014 Regulatory approvals FDA Nivo Melanoma FDA Blinotumomab (BiTE) ALL FDA Pembo Melanoma Japan: Nivo melanoma HPV Vaccine in VIN CTLA4 Identified 2015 Regulatory approvals FDA Nivo Renal Cancer 2016 FDA Daratumumab Regulatory (acd38) approvals Myeloma FDA: Atezolizumab FDA Tvec melanoma Bladder FDA Nivo NonSq FDA: NSCLC Nivolumab chl FDA: pembro Japan: NSCLC Nivolumab RCC : FDA Ipi Nivo Japan: Combination Nivolumab: chl Melanoma Japan: Pembrol: : FDA: Nivo NSCLC Melanoma : Austr: Pembro: Japan: Melanoma Pembro NSCLC Japan NSCLC: NSCLC (1 st & 2 nd line) 2017 Regulatory Approvals FDA: Pembro NSLC 1 st Line Atezolizumab: Lung Avelumab: Merkel Cell CA
5 Immunotherapy for Cancer = Checkpoint Inhibitors
6 What is a Check-Point?
7 T-Cell Activity Is Regulated By Immune Checkpoints to Limit Autoimmunity 1 Dendritic cell TUMOR Inactivated T cell Immune checkpoints, such as CTLA-4, PD-1, LAG-3, and TIM-3 function at different phases in the immune response to regulate the duration and level of the T- cell response. - - Checkpoints CTLA-4 = cytotoxic T-lymphocyte antigen 4; PD-1 = programmed cell death protein 1; LAG-3 = lymphocyte activation gene 3; TIM-3 = T-cell immunoglobulin and mucin protein Pardoll DM. Nat Rev Cancer. 2012;12: Activated T cell Checkpoints LYMPH NODE Inactivated T cell
8 What is a Check-Point Inhibitor?
9 Immunotherapy Immune System Cytokines Antigens Regulatory molecules (CTLA-4, PD-1)
10 Check-Point Inhibitors Approved for Melanoma Anti CTLA4 antibody: Ipilimumab Anti PD-1 inhibitors: pembrolizumab, nivolumab Combination anti CTLA-4 and anti-pd1 (ipilimumab and nivolumab)
11 CTLA-4 Primarily Affects The Priming Phase of T-Cell Activation 1 Priming (Early Stage) Phase of Activation Dendritic cell CTLA-4 Inactivated T cell In healthy tissues, CTLA-4 is thought to function as a dominant off switch broadly shutting down T-cell activity to prevent autoimmunity 1-3 CTLA-4 = cytotoxic T-lymphocyte antigen Pardoll DM. Nat Rev Cancer. 2012;12: ; 2. Ribas A. N Engl J Med. 2012;366: ; 3. Topalian SL et al. Curr Opin Immunol. 2012;24:
12 Clinical Results with Ipilimumab (2 nd and 1st line) Ipilimumab vs vaccine and Ipi + DTIC vs DTIC HR: 0.66 and 0.68 Pre-treated pts Ipi 3 mg/kg +/- gp100 HR: 0.72 First line Ipi 10 mg/kg + DTIC Hodi FS, et al. N Engl J Med. 2010;363: Robert C, et al. N Engl J Med. 2011;364:
13 Immune Checkpoint Inhibitors Provide Durable Long-term Survival for Patients with Advanced Melanoma Overall Survival (%) IPI (Pooled analysis) 1 N=1, Years 1. Schadendorf et al. J Clin Oncol 2015;33: ; 2. Current analysis; 3. Poster presentation by Dr. Victoria Atkinson at SMR 2015 International Congress. 13
14 Ipilimumab became the standard of care in USA for advanced melanoma in 2011 But can we do better?
15 PD-1 Primarily Regulates the Effector Phase of T-Cell Activity Effector Phase Normal cell PD-1 Inactivated T cell The PD-1 immune checkpoint pathway primarily functions during the effector phase of the T-cell response in the peripheral tissue 1 In healthy tissues, PD-1 is thought to limit the activity of antigen-specific T cells to prevent collateral tissue damage during infection 1 In cancer, the PD-1 pathway can be exploited by some tumor cells to inactivate T cells 1 PD-1 = programmed cell death protein Pardoll DM. Nat Rev Cancer. 2012;12:
16 Keynote-006 Front-line Pembrolizumab vs Ipilimumab Patients Unresectable, stage III or IV melanoma 1 prior therapy, excluding anti CTLA-4, PD-1, or PD-L1 agents Known BRAF status b ECOG PS 0-1 No active brain metastases No serious autoimmune disease Stratification factors: ECOG PS (0 vs 1) Line of therapy (first vs second) PD-L1 status (positive c vs negative) R 1:1:1 Pembrolizumab 10 mg/kg IV Q2W Pembrolizumab 10 mg/kg IV Q3W Ipilimumab 3 mg/kg IV Q3W x 4 doses Primary end points: PFS and OS Secondary end points: ORR, duration of response, safety a Patients enrolled from 83 sites in 16 countries. b Prior anti-braf targeted therapy was not required for patients with normal LDH levels and no clinically significant tumor-related symptoms or evidence of rapidly progressing disease. c Defined as membranous PD-L1 expression in 1% of tumor cells as assessed by IHC using the 22C3 antibody.
17 Tumor Response (irrc, investigator)
18 Kaplan-Meier Estimates of Survival (Median Follow-Up, 33.9 mo) OS (%) No Risk Pembro Overall Survival Events, n HR (95% CI) Median, mo (95% CI) Pembrolizumab , ( ) 32.3 (24.5-NR) Ipilimumab ( ) Months 55% 42% % 39% Pembro Ipilimumab Ipilimumab PFS (%) PFS per irrc by Investigator Events, n HR (95% CI) Median, mo (95% CI) Pembrolizumab , ( ) 8.3 ( ) Ipilimumab ( ) Months 34% 15% % 14% Adapted from Robert C, et al. ASCO Abstract 9504.
19 Slide 14
20 Slide 15
21 Anti PD-1 is better than ipilimumab frontline and responses are durable even after stopping treatment But what about combining CTLA-4 and PD-1?
22 Slide 6 Presented By Jedd Wolchok at 2015 ASCO Annual Meeting
23 Updated Response To Treatment NIVO+IPI (N=314) NIVO (N=316) IPI (N=315) ORR, % (95% CI)* 58.9 ( ) 44.6 ( ) 19.0 ( ) Best overall response % Complete response Partial response Stable disease Progressive disease Unknown Median duration of response, months (95% CI) NR (NR NR) 31.1 (31.1 NR) 18.2 (8.3 NR) *By RECIST v1.1; NR = not reached. At the 18-month DBL, the CR rate for NIVO+IPI, NIVO and IPI was 12.1%, 9.8% and 2.2%, respectively Database lock: Sept 13, 2016, minimum f/u of 28 months 23
24 Updated Progression-Free Survival Progression-free Percentage Survival of PFS (%) NIVO+IPI NIVO IPI 50% 43% 18% Median PFS, mo (95% CI) HR (95% CI) vs. IPI HR (95% CI) vs. NIVO NIVO+IPI (N=314) NIVO (N=316) IPI (N=315) 11.7 ( ) 0.42 ( ) 0.76 ( ) Months 43% 37% 12% 6.9 ( ) 0.54 ( ) 2.9 ( ) Patients at risk: NIVO+ IPI NIVO IPI Database lock: Sept 13, 2016, minimum f/u of 28 months 7
25 Updated Survival Data in CheckMate-067 Trial of IPI vs. NIVO vs. IPI/NIVO Median OS, months (95% CI) HR (99.5% CI) vs. IPI HR (99.5% CI) vs. NIVO NIVO + IPI (N=314) NIVO (N=316) IPI (N=315) NR 0.55 ( )* 0.88 ( ) NR (29.1-NR) 0.63 ( )* 20 ( ) *P< Larkin J, et al. AACR Abstract CT075. Database lock: September 13, Minimum follow-up of 28 months
26 Decision Point. Immunotherapy PD-1 alone PD-1/CTLA-4 Combination
27 Checkmate 067: Safety Summary With an additional 19 months of follow-up, safety was consistent with the initial report 1 NIVO+IPI (N=313) NIVO (N=313) IPI (N=311) Patients reporting event, % Any Grade Grade 3-4 Any Grade Grade 3-4 Any Grade Grade 3-4 Treatment-related adverse event (AE) Treatment-related AE leading to discontinuation Treatment-related death, n (%) 2 (0.6) a 1 (0.3) b 1 (0.3) b Most select AEs were managed and resolved within 3-4 weeks (85 100% across organ categories) ORR was 70.7% for pts who discontinued NIVO+IPI due to AEs, with median OS not reached a Cardiomyopathy (NIVO+IPI, n=1); Liver necrosis (NIVO+IPI, n=1). Both deaths occurred >100 days after the last treatment. b Neutropenia (NIVO, n=1); colon perforation (IPI, n=1) Larkin J, et al. NEJM 2015;373:
28 Checkmate 067: Safety Onset Grade 3 4 Treatment-Related Select AEs Skin (n=18) Skin (n=5) Gastrointestinal (n=46) Gastrointestinal (n=7) Endocrine (n=15) Endocrine (n=2) Hepatic (n=60) 14.1 ( ) Longer Time to Resolution Hepatic (n=8) 3.7 ( ) NIVO+IPI Pulmonary (n=3) 6.7 ( ) NIVO Pulmonary (n=1) 11.3 ( ) Renal (n=6) 5.6 ( ) 7.4 ( ) 19.4 ( ) 26.3 ( ) 12.1 ( ) Toxicity Earlier 28.6 ( ) 7.4 ( ) 50.9 ( ) Renal (n=1) Weeks Circles represent medians; bars signify ranges Larkin J et al ECC 2015
29
30 Pembro Keynote 001: 4 Year OS
31 Overall Survival at 5 Years of follow-up for Nivolumab (phase I, n=107) All Patients (events: 69/107), median and 95% CI: 17.3 ( ) NIVO 3 mg/kg (events: 11/17), median and 95% CI: 20.3 (7.2 NR) Probability of Survival Months Number of Patients at Risk All Patients NIVO 3 mg/kg Database lock Oct 2015 Hodi et al. AACR 2016
32 Can a biomarker help us decide?
33 Keynote 001 Pembrolizumab PD-L1 Expression and Response PD-L1 Negative 0% Staining APS = 0 APS, Allred proportion score. Analysis cut-off date: October 18, PD-L1 Positive 1-10% Staining APS = 2 PD-L1 Positive 10-33% Staining APS = 3 PD-L1 Positive % Staining APS = 5 ORR, % (95% CI) APS 0 n = 28 ORR, RECIST v1.1 APS 1 n = 24 Negative APS 2 n = 72 APS 3 n = 54 Positive APS 4 n = 32 APS 5 n = 34 Daud A et al, ASCO 2015
34 OS by Tumor PDL-1 Expression at a 1% Cutoff PD-L1 Expression Level <1% PD-L1 Expression Level 1% <1% PD-L1 NIVO+IPI NIVO IPI 1% PD-L1 NIVO+IPI NIVO IPI Median OS, mo (95% CI) NR (26.5 NR) 23.5 (13.0 NR) 18.6 ( ) Median OS, mo (95% CI) NR NR 22.1 ( ) 100 HR (95% CI) vs NIVO 0.74 ( ) 100 HR (95% CI) vs NIVO 1.03 ( ) OS (%) % 49% 41% OS (%) % 67% 48% ORR of 54.5% for NIVO+IPI and 35.0% for NIVO 10 ORR of 65.2% for NIVO+IPI and 55.0% for NIVO Months Patients at risk: NIVO+IPI NIVO IPI Months Patients at risk: NIVO+IPI NIVO IPI
35 PFS and OS Subgroup Analyses (All Randomized Patients) Descriptive comparison between NIVO+IPI and NIVO Patients Unstratified Hazard Ratio Unstratified Hazard Ratio (95% CI) Subgroup NIVO+IPI NIVO PFS OS PFS OS Overall <65 years years BRAF Mutant BRAF Wild-type ECOG PS = ECOG PS = M0/M1a/M1b M1c LDH ULN LDH > ULN LDH > 2 x ULN PD-L1 5% PD-L1 <5% NIVO+IPI NIVO NIVO+IPI NIVO 2 35
36 Overview Current Therapy for Melanoma BRAF-WT patient BRAF+ patient Immunotherapy side effects management and practical considerations
37 Melanoma is not one disease (Curtin et al, N Engl J Med 353: , 2005) B-RAF: 50% c-kit: 5-10% c-kit: 10-20% c-kit:15-30%
38 MAPK Pathway Growth Factors RAS BRAF MEK ERK Cell proliferation and survival
39 BRAF Mutation Growth Factors RAS BRAF BRAF mutation is present in ~50% of melanomas MEK ERK Increased cell proliferation and survival
40 MAPK Pathway Targeted Therapy BRAFi (dabrafenib) PFS HR, 0.37 vs DTIC 1 Hyperproliferative skin AEs BRAFi (vemurafenib) PFS HR, 0.38 vs DTIC 2 Hyperproliferative skin AEs PFS HR, 0.45 vs chemotherapy 3 MEKi (trametinib) RAS mutbraf MEK perk Proliferation, Survival, Invasion, Metastasis BRAFi + MEKi ph III studies Dabrafenib + trametinib (D + T) PFS HR, 0.67 vs dabrafenib 4 OS HR, 0.71 vs dabrafenib 4 PFS HR, 0.56 vs vemurafenib 5 OS HR, 0.69 vs vemurafenib 5 Vemurafenib + cobimetinib PFS HR, 0.58 vs vemurafenib 6 OS HR, 0.70 vs vemurafenib 6 Decreased hyperproliferative skin AEs 4,5,6 1. Hauschild A, et al. Lancet. 2012;380(9839): McArthur GA, et al. Lancet Oncol. 2014;15(3): Flaherty KT, et al. N Engl J Med. 2012;367(2): Long GV, et al. Lancet. 2015;386(9992): Robert C, et al. N Engl J Med. 2015;372(1): Atkinson V, et al. Presented at:society for Melanoma Research 2015 Congress.
41 Decision Point. BRAF mutation test BRAF V600 mutation negative Immunotherapy Immunotherapy Or BRAF V600 mutation positive MAP-K Targeted Therapy
42 Slide 34 Presented By Axel Hauschild at 2014 ASCO Annual Meeting
43 Phase III KEYNOTE-006: PFS in Prespecified Subgroups Overall Male Female Age <65 y Age ³65 y White race US Rest of world ECOG PS ECOG PS Favors Pembro Favors IPI 10 Hazard Ratio Pembrolizumab Q2W vs ipilimumab Analysis cut-off date: September 3, First-line therapy Second-line therapy PD-L1 positive PD-L1 negative BRAF wild type BRAF mutant, 95 prior anti-braf 96 BRAF mutant, no prior anti-braf No prior immunotherapy Favors Pembro Favors IPI 10 Pembrolizumab Q3W vs ipilimumab Hazard Ratio
44 BRAF Inhibitors Second line Vemurafenib 1 Dabrafenib 2 Phase RR 56% 57% 57% 56% 59% 59% PFS OS Chapman PB, et al. N Engl J Med 2011;364: (updated Chapman et al. ASCO 2012); Sosman JA, et al. N Engl J Med 2012;366: ; 2. Hauschild A, et al. Lancet 2012;380: (updated Hauschild et al. ASCO 2013); Ascierto PA, et al. J Clin Oncol 2013; 31:
45 D+T: Long Term FU LDH < ULN and < 3 metastatic sites (ITT) Progression-Free Survival Overall Survival Progression-Free Survival, % % 40 25% 25% 20 8% 8% 8% Patients at risk, n Time From Randomization, months Patients at risk, n Time From Randomization, months Overall Survival, % % 57% 60 51% 58% 40 42% 31% 20 PRESENTED BY J WEBER AT ASCO 2017
46 Contemplating the Options EA6134 Anti-PD1 therapy BRAF-targeted therapy
47 Combining Immunotherapy and Targeted Therapy for Melanoma? Improved Survival With Ipilimumab in Patients with Metastatic Melanoma 1 Improved Survival With Vemurafenib in Melanoma With BRAF V600E Mutation 2 Percent Alive Immunotherapy Years Percent Alive Targeted therapy Years Percent Alive 0 Combination??? Years Modified from: Ribas A, et al. Clin Cancer Res. 2012;18(2): Hodi FS, et al. N Engl J Med. 2010;363(8): Chapman PB, et al. N Engl J Med. 2011;364(26):
48 Targeted-Immuno Triplets: BRAF + MEK + PD1/L1 Dabrafenib+Trametinib +Durvalumab Dabrafenib+Trametinib +Pembrolizumab Vemurafenib+Cobimetinib +Atezolizumab 100 Multiple Triplet Combinations Launching Into Phase III: Dabrafenib + Trametinib + Pembrolizumab Dabrafenib + Trametinib + PDR Vemurafenib + Cobimetinib Atezolizumab Time, weeks Change From Baseline in Sum of Longest Diameter of Target Lesion, % Change From Baseline, % Ribas et al. ASCO 2015 Ribas et al. ASCO 2016 Hwu et al. ECCO 2016
49 Overview Current Therapy for Melanoma BRAF-WT patient BRAF+ patient Immunotherapy side effects management and practical considerations
50 Practical Issues in Management Assessing Response Recognizing and managing toxicity
51 Immunotherapy: Heterogeneous Response Patterns Change From Baseline SPD (%) Change From Baseline SPD (%) 4 distinct response patterns associated with favorable OS Response in baseline lesions Relative Day From Randomization Date Response after initial increase in tumor volume Wolchok JD, et al. Clin Cancer Res. 2009;15: N Relative Day From Date of First Dose SPD (mm 2 ) SPD (mm 2 ) Change From Baseline SPD Change (%) From Baseline SPD (%) SD with slow decline in tumor volume Relative Day From Date of First Dose 25 0 Tumor volume reduction after new lesions N N N N N N Relative Day From Date of First Dose SPD (mm 2 ) SPD (mm 2 )
52 Immune-Related Patterns of Response with anti-ctla4: Melanoma Response After the Appearance and Subsequent Disappearance of New Lesions Pretreatment Week 20: Regression 3 mg/kg Ipilimumab Q3W X 4 Pseudoprogression Tumor Flare Week 12: Progression New lesions Week 36: Still Regressing Courtesy of J. Wolchok. Source: Wolchok et al, ASCO 2008 (Abstract #3020).
53 Response Assessment: RECIST vs. irrc Category RECIST v1.1 mwho irrc Measurement: tumor burden Complete Response (CR) Unidimensional: Sum Longest Diameter Bidimensional: Sum Product Diameter (SPD) Disappearance of all target and non-target lesions Confirmation required: two consecutive observations no less than 4 weeks apart Partial Response (PR) 30% in tumor burden compared to baseline Confirmation required Progressive Disease (PD) 20% + 5 mm absolute in tumor burden compared to nadir New lesion No confirmation required 50% in tumor burden compared to baseline Confirmation required 25% in tumor burden compared to nadir New lesion No confirmation required Bidimensional: SPD 50% in tumor burden compared to baseline Confirmation required 25% in tumor burden compared to baseline, nadir, or reset baseline New lesions added to tumor burden Confirmation required Stable Disease Neither PR nor PD 1. Agarwala SS. Semin Oncol Miller AB et al. Cancer 1981;47: Wolchok JD et al. Clin Cancer Res 2009;15(23):
54 Immune Checkpoint Blockade Key Points About Response Evaluation Antitumor activity may appear to be delayed compared to response times associated with cytotoxic therapies Patients may experience response after the appearance of progressive disease Development of progressive disease should be confirmed prior to discontinuation of therapy Development of small lesions in the presence of other responsive lesions may be clinically insignificant Responses are durable among CRs but also in PR and SD Agarwala SS. Semin Oncol
55 Practical Issues in Management Assessing Response Recognizing and managing toxicity
56 iraes Associated With Immuno-Oncology Therapies a Hepatic Autoimmune hepatitis 1,3 ALT/AST increases 1,2 Endocrine Hypophysitis 1 3 Thyroiditis 1,3 Type 1 diabetes 4 Respiratory Renal Pneumonitis 1,3 Nephritis 1 Renal failure 5 Gastrointestinal Skin Colitis/diarrhea 1,2 Macropapular rash 1 Pruritus 1,2 Neuromuscular Peripheral sensory neuropathy 1 a The AEs described here represent some but not all iraes that may occur with immune checkpoint inhibitor therapies. 1. Teply BA et al. Oncology (Williston Park). 2014;28 Suppl 3: Hodi FS et al. N Engl J Med. 2010;363(8): Topalian SL et al. N Engl J Med. 2012;366(26): Mellati M et al. Diabetes Care. 2015;38(9):e137 e Forde PM et al. Anticancer Res. 2012;32(10):
57 CTLA-4 Blockade With Ipilimumab Kinetics of iraes in Melanoma Toxicity Grade Weber JS, et al. J Clin Oncol Time (weeks)
58 PD-1 Blockade: Kinetics of iraes in Melanoma Approximate proportion of patients (%) Time (weeks) Skin Gastrointestinal Endocrine Hepatic Pulmonary Renal Weber JS, et al. ASCO
59 Most Clinically Relevant iraes GI diarrhea Pulmonary pneumonitis Endocrine thyroid, pituitary Dermatologic Hepatic
60 Gastrointestinal Toxicity NCI CTCAE v4.0 Grade 1 Grade 2 Grade 3 Grade 4 Colitis Asymptomatic, pathologic or radiographic findings only Abdominal pain; mucus or blood in stool Abdominal pain, fever, change in bowel habits with ileus; peritoneal signs Life-threatening consequences (eg, perforation, bleeding, ischemia, necrosis, toxic megacolon) Diarrhea Increase of <4 stools per day over CLOSE baseline; mild increase MONITORING in ostomy output compared TREAT to baseline SYMPTOMS Increase of 4-6 stools per day over baseline; ORAL IV fluids CORTICOIDS indicated IF SYMPTOMS <24 hours; moderate increase >5 DAYS in ostomy output compared to baseline; not interfering with ADL Increase IV HIGH of DOSE 7 stools CORTICOIDS Life-threatening per day over baseline; consequences incontinence; CONSIDER ALTERNATIVE fluids (eg, hemodynamic IMMUNOSUPPRESSIVE 24 hours; THERAPY collapse) hospitalization; severe increase CONSULT in ostomy GASTROENTERELOGIST output compared to baseline; interfering with ADL Enteritis Asymptomatic, pathologic or radiographic findings only Abdominal pain; mucus or blood in stool Abdominal pain, fever, change in bowel habits with ileus; peritoneal signs Life-threatening consequences (eg, perforation, bleeding, ischemia, necrosis)
61 Gastrointestinal (colitis, diarrhea), Grade 1 Ø Continue therapy, treat symptomatically with loperamide and/or diphenoxylate/atropine. Ø Follow-up: Monitor closely for worsening symptoms, educate patient to report worsening immediately. Ø If symptoms worsen: treat as grade 2 or 3/4
62 Gastrointestinal (colitis, diarrhea), Grade 2 Ø Hold therapy; treat symptomatically as for grade 1; check C. difficile titres and stool cultures. Ø Follow-up: Resume therapy if symptoms improve to grade 1 Ø If symptoms persist > 5 days or recur: Ø -Initiate mg/kg per day methylprednisolone or oral equivalent -When symptoms improve to grade 1, taper steroids over 1 mo, consider prophylactic antibiotics and resume therapy Ø If symptoms worsen or persist for >3 days with oral steroids: treat as grade 3/4
63 Gastrointestinal (colitis, diarrhea), Grade 3 Ø -Consider permanent discontinuation of therapy -Consider hospital admission mg/kg/day IV methylprednisolone or equivalent -Add prophylactic antibiotics for opportunistic infections -Consider endoscopy; check C. difficile titres and cultures Ø Follow-up: If symptoms improve, continue steroids until grade 1, then taper over at least 1 month. Ø If symptoms persist > 3 days or recur after improvement: Add infliximab 5 mg/kg/day (if no contraindication, and should not be used in cases of perforation or sepsis)
64 Gastrointestinal (colitis, diarrhea), Grade 4 Ø -Permanently discontinue therapy -Hospital admission mg/kg/day IV methylprednisolone or equivalent -Consider endoscopy ; check C Difficile titres and cultures -Consult GI consult Ø Follow-up: If symptoms improve, continue steroids until grade 1, then taper over at least 1 month Ø If symptoms persist > 3 days or recur after improvement: Add infliximab 5 mg/kg/day (if no contraindication, and should not be used in cases of perforation or sepsis)
65 Pulmonary (pneumonitis), Grade 1 Ø -Obtain chest x-ray Ø -Consider holding therapy Ø -Monitor for symptoms every 2-3 days Ø -Consider pulmonary and ID consults Ø Follow-up: Re-image at least every 3 weeks Ø If symptoms worsen: Treat as grade 2 or grade 3/4
66 Pulmonary (pneumonitis), Grade 2 Ø -Hold therapy -Consider chest CT -Pulmonary consult -Monitor symptoms daily, strongly consider hospitalization -1.0 mg/kg/day IV methylprednisolone or oral equivalent -Consider bronchoscopy Ø Follow-up: Re-image every 1-3 days Ø If symptoms improve to baseline: Taper steroids over 1 month; resume therapy and consider prophylactic antibiotics Ø If symptoms persist or worsen after 2 wks: Treat as grade 3/4
67 Pulmonary (pneumonitis), Grade 3/4 Ø -Permanently discontinue therapy -Hospitalize? -Pulmonary and ID consults -2-4 mg/kg/day IV methylprednisolone or IV equivalent -Consider bronchoscopy, lung biopsy Ø Follow-up: If symptoms improve to baseline: Taper steroids over 6 weeks Ø If symptoms persist or worsen after 48 hrs: Add additional infliximab, cyclophosphamide, IVIG, or mycophenolate mofetil
68 Ø Continue therapy Endocrine: Thyroid Asymptomatic TSH elevation Ø Follow-up: -If TSH < 0.5 X lower limit of normal, or TSH > 2 x upper limit of normal, or consistently out of range in 2 subsequent measurements: include free T4 at subsequent cycles as indicated Ø -Consider endocrinology consult and start hormone replacement if TSH > 2X ULN
69 Endocrine: Thyroid Symptomatic hypothyroidism Ø -Monitor TFTs every 1 to 3 weeks Ø -Consider pituitary MRI Ø -Endocrinology consult Ø -Initiate hormone replacement therapy Hypothyroidism
70 Endocrine: hypophysitis, not symptomatic Ø -Hold therapy -Evaluate pituitary function -Consider MRI with pituitary cuts -Initiate hormone replacement with abnormal pituitary scan -Cortisol replacement should be initiated 1 week prior to levothyroxine administration Ø Follow-up: -If improved (with or without hormone replacement), can resume treatment -Consider endocrinology consult
71 Endocrine: hypophysitis, symptomatic Ø -Permanently discontinue therapy -1 mg/kg/day prednisone or equivalent -Evaluate pituitary axis function (morning cortisol, ACTH, TSH, LH, FSH, estradiol/testosterone, prolactin) -MRI with pituitary cuts Ø -Taper steroids over 1 month, then initiate hormone replacement if symptomatic with abnormal pituitary scan -IV therapy if hypotensive -Endocrinology consult
72 Dermatologic, rash, Grade 1/2 Ø Continue therapy, treat symptomatically (antihistamines, hydroxyzine and/or topical steroids) Ø Follow-up: Monitor closely for worsening symptoms Ø If rash persists for > 1 wk, recurs and/or worsens: -Hold therapy -Consider a biopsy -Consider mg/kg per day IV methylprednisolone or oral equivalent -When symptoms improve to grade 1, taper steroids over 1 mo, consider prophylactic antibiotics and resume therapy Ø If symptoms worsen: Treat as grade 3/4
73 Dermatologic, rash, Grade 3 Ø -Hold therapy mg/kg/day IV methylprednisolone or equivalent -Consider dermatology consultation -Consider skin biopsy Ø Follow-up: Continue steroids until grade 2, then taper over at least 1 month before resuming therapy
74 Dermatologic, rash, Grade 4 Ø -Permanently discontinue therapy mg/kg/day IV methylprednisolone or equivalent -Consult dermatology -Consider skin biopsy Ø Follow-up: Continue steroids until grade 2, then taper over at least 1 month
75 Hepatitis: Management LFTs >8x or total bilirubin >5x Intensified monitoring; labs every 1-3 days until begin to resolve High dose steroids, eg, methylprednisolone 1-2 mg/kg/day; if LFTs decrease convert to oral steroids If after 3 days, no improvement or rebound, add mycophenolate 1 g BID PO If no improvement in 5-7 days, add tacrolimus 0.1 to 0.15 mg/kg/day IV (trough level 5-20 ng/ml)
76 Some Pearls We Have Learned Along the Way For grade 3 or 4 toxicity and use of HD steroids, taper SLOWLY over at least 4 weeks Patients receiving > 4-6 weeks of steroids may require Pneumocystis carinii prophylaxis. Numbers don t always match clinical presentation TSH, lipase Delayed side-effects may occur Even in year 2 of treatment with anti-pd1
77 What do I do in my clinic? Separate appointment with nurse for detailed education Preferably on a separate day Verbal and written instructions Refresher course periodically and reminder at each visit Check routine labs including TSH before each dose Regular phone call with nurse depending upon need Education that more drug is not always better
78 Summary Benefit with immunotherapy may occur after initial progression Responses can be durable after stopping therapy Toxicity with anti-pd1 is less than anti-ctla4 Toxicities may be delayed and unpredictable Team Approach!
79 Summary & Conclusions Immunotherapy with CPB is a front-line option for all patients Anti PD1 is better than anti-ctla4 Combination may be better but higher toxicity; Anti-PD1 alone may be enough for most patients BRAF mutated patients may receive MAP-kinase directed therapy or immunotherapy Correct sequence is controversial Combination BRAF/MEK is better than BRAF alone Unique aspects of immunotherapy need to be inegrated into clinical practice Pseudoprogression Immune-related adverse events
80
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationMedical Treatment for Melanoma Sanjiv S. Agarwala, MD
Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Disclosures None Overview
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationCANCER IMMUNOTHERAPY. Pocket Guide
CANCER IMMUNOTHERAPY Pocket Guide Unique Clinical Features Tumor Response Kinetics Response patterns associated with immune checkpoint blockade may differ from those associated with conventional therapies,
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationImmunotherapy: Toxicity Management. Dr. Megan Lyle Medical Oncologist Liz Plummer Cancer Care Centre Cairns Hospital
Immunotherapy: Toxicity Management Dr. Megan Lyle Medical Oncologist Liz Plummer Cancer Care Centre Cairns Hospital Disclosures Honoraria and travel support from BMS, MSD, Novartis Advisory board for MSD
More informationImmunotherapy for Metastatic Malignant Melanoma. Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg
Immunotherapy for Metastatic Malignant Melanoma Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg Survival in Melanoma by Stage Proportion Surviving 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Stage
More informationOvercoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016
Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016 Overcoming toxicity A new context for evaluating toxicity
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationTreatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC
Treatment and management of advanced melanoma: 2018 Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Disclosure Paul B. Chapman, MD Nothing to disclose. Off
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationImmunoterapia e melanoma maligno metastatico: siamo partiti da li. Vanna Chiarion Sileni Istituto Oncologico Veneto
Immunoterapia e melanoma maligno metastatico: siamo partiti da li Vanna Chiarion Sileni Istituto Oncologico Veneto Vanna.chiarion@iov.veneto.it Metastatic Melanoma Available Treatment: 197 217 Zelboraf
More informationEvolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes. Disclosures
Evolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes Fall Managed Care Forum November 11, 2016 Matthew Taylor, M.D. Disclosures Consulting/Advisory
More informationNew Therapeutic Approaches to Malignant Melanoma
2018 Master Class for Oncologists New Therapeutic Approaches to Malignant Melanoma F. Stephen Hodi, M.D. Dana-Farber Cancer Institute, Boston, MA Disclosure I have nothing to disclose. Off Label/Investigational
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationBC Cancer Protocol Summary for Treatment of Advanced Non- Small Cell Lung Cancer Using Pembrolizumab
BC Cancer Protocol Summary for Treatment of Advanced Non- Small Cell Lung Cancer Using Pembrolizumab Protocol Code Tumour Group Contact Physician ULUAVPMB Lung Dr. Christopher Lee ELIGIBILITY: Advanced
More informationImmunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationOPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS
OPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS Alberto Fusi Charité Comprehensive Cancer Centre Berlin, Germany 1 Immune check point blockade with CTLA-4, anti-pd-1
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationBCCA Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Nivolumab
BCCA Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Nivolumab Protocol Code Tumour Group Contact Physician USMAVNIV Skin and Melanoma Dr. Kerry Savage ELIGIBILITY: Unresectable
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationTerapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico
Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,
More informationWhat we learned from immunotherapy in the past years
What we learned from immunotherapy in the past years Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure
More informationApproaches To Treating Advanced Melanoma
Approaches To Treating Advanced Melanoma Suraj Venna, MD Medical Director, Melanoma and Cutaneous Oncology Inova Schar Cancer Institute Associate Professor, VCU Fairfax VA Disclosures No relevant disclosures
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationBest Practices in the Treatment and Management of Metastatic Melanoma. Melanoma
Best Practices in the Treatment and Management of Metastatic Melanoma Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology Assistant
More informationMELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona
MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationCheckpoint inhibitors: Strategies to checkmate T-cell mediated toxicity. Disclosure Statement. Learning Objectives
Checkpoint inhibitors: Strategies to checkmate T-cell mediated toxicity Adam J. DiPippo, PharmD Clinical Pharmacy Specialist Leukemia Texas Society of Health-System Pharmacists 2017 Annual Seminar April
More informationOptimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma
Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma Dr. J.L.Manzano S. Oncología Médica H. Germans Trias i Pujol, ICO-Badalona PRBB Auditorium,
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationCombination Approaches in Melanoma: A Balancing Act
Combination Approaches in Melanoma: A Balancing Act Antoni Ribas, MD, PhD Jonsson Comprehensive Cancer Center University of California Los Angeles Los Angeles, California Advances in the Treatment of Metastatic
More informationAdvances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016
Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationComplications of Immunotherapy
Complications of Immunotherapy Sarah Norskog, PharmD, BCOP Oncology Pharmacy Specialist University of Colorado Hospital Disclosures I have no relevant financial relationships with commercial interests
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationMANAGEMENT OF IMMUNE-RELATED SIDE EFFECTS OF IMMUNE CHECKPOINT INHIBITORS
MANAGEMENT OF IMMUNE-RELATED SIDE EFFECTS OF IMMUNE CHECKPOINT INHIBITORS John B.A.G. Haanen MD PhD CONTENT OF THIS PRESENTATION General aspects of immune related adverse events related to immune checkpoint
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationNursing Perspective on iraes: Patient Education, Monitoring and Management
Nursing Perspective on iraes: Patient Education, Monitoring and Management Rebecca Lewis, CRNP Nurse Practitioner University of Pittsburgh-HCC Shadyside Disclosures No relevant financial relationships
More informationCancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Patrick Medina, Pharm.D., BCOP Professor The University of Oklahoma College of Medicine Stephenson Cancer Center Faculty Disclosure
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine
ASCO 214: The Future is Here George W. Sledge MD Stanford University School of Medicine What I Will Talk About Two paths to a Cure Slicing the pie MelMng the snowflake The Past Isn t Dead Improving PaMent
More information7.3 Suggested Evaluation and Treatment for Immunerelated Adverse Events Gastrointestinal Tract
7.3 Suggested Evaluation and Treatment for Immunerelated Adverse Events Early diagnosis and treatment intervention for high-grade iraes can help prevent the occurrence of complications, such as GI perforation.
More informationIpilimumab in Melanoma
Ipilimumab in Melanoma Indication: Advanced (unresectable or metastatic) melanoma in adults who have received prior therapy LCNDG criteria to be met: Histologically confirmed unresectable stage III or
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced Melanoma
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced Melanoma This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationToxicity of Systemic Melanoma Therapies. Alex Guminski Melanoma Institute Australia Royal North Shore Hospital University of Sydney
Toxicity of Systemic Melanoma Therapies Alex Guminski Melanoma Institute Australia Royal North Shore Hospital University of Sydney Disclosures Advisory Board Novartis, BMS, Sanofi, Pfizer Travel support
More informationNew treatments in melanoma
New treatments in melanoma Paolo A. Ascierto, MD Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy Meta-analysis of Phase II cooperative group trials in metastatic stage IV melanoma to determine
More informationUpdate on Targeted Therapy in Melanoma
Update on Targeted Therapy in Melanoma Seville June 2013 James Larkin FRCP PhD London UK Overview What are the targets in melanoma? BRAF / KIT / NRAS / GNAQ / MEK DNA / microtubules CTLA4 / PD1 / PDL1
More informationBCCA Protocol Summary for Treatment of Metastatic or Advanced Renal Cell Carcinoma Using Nivolumab
BCCA Protocol Summary for Treatment of Metastatic or Advanced Renal Cell Carcinoma Using Nivolumab Protocol Code Tumour Group Contact Physician UGUAVNIV Genitourinary Dr. C. Kollmannsberger ELIGIBILITY:
More informationManaging immune related toxicity. Karijn Suijkerbuijk May 27 th 2017
Managing immune related toxicity Karijn Suijkerbuijk May 27 th 2017 Disclosures Advisory role: BMS, Merck Travel support: Amgen, Novartis, Roche Whybother? Patients are dying from toxicity Eggermont ipilimumab
More informationBCCA Protocol Summary for Treatment of Advanced Non-Small Cell Lung Cancer Using Nivolumab
BCCA Protocol Summary for Treatment of Advanced Non-Small Cell Lung Cancer Using Nivolumab Protocol Code Tumour Group Contact Physician ULUAVNIV Lung Dr. Christopher Lee ELIGIBILITY: Advanced non-small
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationMelanoma- Fighting the Dark Side
Melanoma- Fighting the Dark Side Anna C. Pavlick, BSN, MSc, DO, MBA Professor of Medicine and Dermatology Director, NYU Melanoma Program Director, NYU Clinical Trials Office NYU Perlmutter Cancer Center
More informationToxicity from Checkpoint Inhibitors. James Larkin FRCP PhD
Toxicity from Checkpoint Inhibitors James Larkin FRCP PhD Disclosures Research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): BMS, Eisai, GSK, MSD, Novartis, Pfizer, Roche/Genentech
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationManaging Checkpoint Inhibitor Toxicities. Megan L. Menon, Pharm.D., BCOP Roswell Park Cancer Institute
Managing Checkpoint Inhibitor Toxicities Megan L. Menon, Pharm.D., BCOP Roswell Park Cancer Institute Approved Indications Ipilimumab Nivolumab Pembrolizumab* Atezolizumab Avelumab Durvalumab Ipi + Nivol
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationCancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Emily Borders, Pharm.D., M.S., BCOP Oncology Clinical Pharmacist Stephenson Cancer Center Faculty Disclosure Learning Objectives
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationCancer Progress. The State of Play in Immuno-Oncology
Cancer Progress The State of Play in Immuno-Oncology Axel Hoos, MD, PhD VP, Oncology R&D, Glaxo Smith Kline Co-Director, Cancer Immunotherapy Consortium Key Drivers in Immuno-Oncology Science Methods Combinations
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationImmune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities Jeryl Villadolid
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationMelanoma Clinical Trials and Real World Experience
Melanoma Clinical Trials and Real World Experience Paul Lorigan University of Manchester Manchester, UK www.christie.nhs.uk/melanoma Melanoma Bridge, Naples 214 New Benchmarks for Phase II Trials OS at
More informationCancer Immunotherapy: Promises and Challenges. Disclosures
Cancer Immunotherapy: Promises and Challenges David B. Page, MD Medical Oncology PMG East Hematology & Oncology Earle A. Chiles Research Institute Portland, Oregon Disclosures Consulting: Celldex, Nektar,
More informationIMMUNOTARGET THERAPY: ASPETTI GENERALI
IMMUNOTARGET THERAPY: ASPETTI GENERALI Alessandro Minisini Dipartimento di Oncologia Azienda Ospedaliero Universitaria Udine Verona, 19 settembre 2015 HALLMARKS OF CANCER Douglas Hanahan, Robert A. Weinberg,
More informationImmune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes
Immune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes Geoffrey T. Gibney, MD Associate Professor Co-leader, Melanoma Disease Group Lombardi Comprehensive Cancer Center
More informationCANCER IMMUNOTHERAPY Presented by John A Keech Jr DO MultiCare Regional Cancer Center
CANCER IMMUNOTHERAPY 2018 Presented by John A Keech Jr DO MultiCare Regional Cancer Center Successful anti-cancer immunity is autoimmunity Green, The Scientist, 2014 Immunotherapy strategies Cancer vaccines
More informationMANAGEMENT OF IMMUNE-RELATED GI AND LIVER TOXICITY
MANAGEMENT OF IMMUNE-RELATED GI AND LIVER TOXICITY Alberto Fusi Charité Comprehensive Cancer Centre - Berlin St. George s University - London TAO Meeting - Cancer Toxicity Management Paris - 8th-9th December
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationReview of immunotherapy in melanoma
Review of immunotherapy in melanoma Surein Arulananda, 1,2,3 Elizabeth Blackley, 1 Jonathan Cebon 1,2,3 1. Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia. 2. Cancer Immunobiology
More informationInnovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD
Innovations in Immunotherapy - Melanoma Systemic Therapies October 27, 2018 Charles L. Bane, MD Melanoma Prognosis Survival at 10 years Stage I: 90% Stage II: 60% Stage III: 40% Stage IV: 10% 2 Indications
More informationENDOCRINE ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT IMMUNOTHERAPY
ENDOCRINE ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT IMMUNOTHERAPY Lauren Clarine DO, Renil Rodriguez Martinez MD, Matthew Levine MD, Amy Chang MD, and Megan McGarvey MD May 6, 2017 Immune checkpoint inhibitors
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationManagement of Immune Checkpoint Inhibitor Related Toxicities
Management of Immune Checkpoint Inhibitor Related Toxicities Katie Wolfram, PharmD Clinical Pharmacist, Oncology Memorial Hospital of South Bend A Webinar for HealthTrust Members November 12, 2018 Disclosures
More informationMelanoma Immunotherapy. Nursing Perspective on Immune-Related Adverse Events: Patient education, Monitoring & Management
Melanoma Immunotherapy Nursing Perspective on Immune-Related Adverse Events: Patient education, Monitoring & Management Mike Buljan, NP UCSF Medical Center Melanoma Oncology Disclosures None Only FDA-approved
More informationPhase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma
Phase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma Abstract #3003 Ribas A, Butler M, Lutzky J, Lawrence D, Robert C, Miller W,
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing
ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma
More informationNew Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy
New Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationImmunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS)
Immunotherapies in melanoma: regulatory perspective Jorge Camarero (AEMPS) Challenges for the approval of anti-cancer immunotherapeutic drugs EMA-CDDF joint meeting, London 4-5 February 2016 disclaimers
More informationSafety Immune Related Adverse Events (irae) Focus on NSCLC Aaron Hansen, BSc, MBBS, FRACP
Safety Immune Related Adverse Events (irae) Focus on NSCLC Aaron Hansen, BSc, MBBS, FRACP Division of Medical Oncology and Hematology Bras Drug Development Program Princess Margaret Cancer Centre, Toronto,
More informationPembrolizumab: First in Class for Treatment of Metastatic Melanoma
Section Editors: Christopher J. Campen and Beth Eaby-Sandy Pembrolizumab: First in Class for Treatment of Metastatic Melanoma CARRIE BARNHART, PharmD From Billings Clinic Cancer Center, Billings, Montana
More informationBCCA Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab
BCCA Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab Protocol Code Tumour Group Contact Physician USMAVIPI Skin and Melanoma Dr. Kerry Savage ELIGIBILITY: Unresectable
More information